HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $497, high $798, with mid-point at $647.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$647
Margin of safety
+34.1%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$426.37Price
Low $496.77
Mid $647.26
High $798.49
HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Local market density and scale
Local market density and scale advantages driving industry-leading margins.
Demographic tailwinds with an aging
Demographic tailwinds with an aging population ensuring consistent volume.
Bull thesis
Market under-appreciates the durability of HCA's local market density and the resultant ROIC/WACC spread.
Our financial-history view of HCA (HCA) covers revenue, gross profit, operating income, and net income across the past five fiscal years, with year-over-year growth and margin context for each line.
The revenue trajectory is reported in the financial-history section with year-over-year growth rates. Direction and acceleration are summarised inline; the full table sits within the parent financials tab.
We track operating income alongside operating margin so the reader can separate top-line growth from operating leverage. The numbers analysis subsection flags one-offs, restructuring, and stock-based-compensation effects when material.
Net income is shown together with EPS so dilution and buybacks are visible alongside profit. Where reported net income diverges materially from operating cash flow, the discrepancy is called out in the numbers-analysis subsection.
FAQ
HCA — frequently asked questions
Based on our latest analysis, HCA looks meaningfully undervalued. The current price is $426 versus a composite fair-value midpoint of $647 (range $497–$798), which implies roughly 51.8% upside to the midpoint.
Our composite fair-value range for HCA is $497–$798, with a midpoint of $647. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for HCA's archetype.
Our current rating for HCA is Strong Buy with a confidence score of 88/100. HCA is rated Strong Buy at $426.37 versus the reconciled fair value midpoint of $647.26, implying +51.81% upside/downside. Confidence is separately disclosed at 88/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for HCA are: Severe Reimbursement Cuts; Structural Labor Shortage; Debt Cost Spiral. The single biggest risk is Severe Reimbursement Cuts: Government payers drastically compress Medicare/Medicaid rates to manage ballooning deficits, crushing margins.
Our current rating for HCA is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($497–$798) versus the current price of $426.
HCA is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for HCA.